Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
92 Infertility Trials Near You
Power is an online platform that helps thousands of Infertility patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerLaser Assisted Hatching for Infertility
Marlton, New Jersey
This study aims to assess the clinical significance of cleavage stage (Day 3) assisted hatching compared to assisted hatching at the blastocyst stage (Day 5,6,7) of embryo development at the time of trophectoderm (TE) biopsy for patients undergoing in vitro fertilization (IVF) and preimplantation genetic testing for aneuploidy (PGT-A) for treatment of their infertility.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 42
Sex:Female
Key Eligibility Criteria
Disqualifiers:Failed IVF, Donor Oocyte, Gestational Carriers, Others
75 Participants Needed
FET Protocols for Infertility
Marlton, New Jersey
The goal of this randomized clinical trial is to compare frozen embryo transfer protocols in patients undergoing a second frozen embryo transfer (FET) after a unsuccessful first programmed FET cycle as a possible treatment for people undergoing infertility treatment.
The purpose of this research study is to:
* Determine if there is a difference between FET protocols in patients who require a second FET cycle.
* Investigate if switching the FET protocol after a failed programmed cycle is beneficial for patients undergoing a second FET cycle.
* Examine pregnancy outcomes including obstetrical and neonatal outcomes (if applicable)
* Obtain uterine flexibility/stiffness measurements via transvaginal ultrasound prior to the embryo transfer procedure. This is called shear wave elastography.
Participants will be randomized in their second FET transfer attempt to either another programmed protocol or a modified natural protocol.
No Placebo Group
Trial Details
Trial Status:Terminated
Age:18 - 53
Sex:Female
Key Eligibility Criteria
Disqualifiers:Not Listed
9 Participants Needed
Incubators for Infertility
Basking Ridge, New Jersey
The goal of this study is to determine if benchtop incubators improve the number of embryos making it to the blastocyst stage of development (about 4-6 days after fertilization) in people undergoing in vitro fertilization (IVF) treatment for their infertility.
* Test the effectiveness of the benchtop incubator.
* Determine if the number of embryos reaching the blastocyst stage of embryo development (the stage that the embryos are biopsied for PGT-A and frozen) is improved in the benchtop incubator compared to the box incubator.
* Compare embryology outcomes between the two incubator types.
* Investigate transfer and pregnancy outcomes.
* Expand the knowledge surrounding the impact of the incubator on IVF outcomes. Patients will have their mature oocytes collected at the egg retrieval procedure split into two groups and randomized to be cultured in both incubator types.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 41
Sex:Female
Key Eligibility Criteria
Disqualifiers:Failed IVF, Donor Oocyte, Others
252 Participants Needed
PRP Therapy for Infertility
Basking Ridge, New Jersey
To determine the effectiveness of an intrauterine PRP infusion on endometrial thickness and in vitro fertilization (IVF) outcomes in a population of infertile women with a history of unresponsive thin endometrium.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Fewer Than 2 Cycles, Pregnancy, Thrombosis, Thrombophilia, Others
Must Not Be Taking:Anticoagulants, Adjunctive Therapies
62 Participants Needed
Sperm Selection Methods for Infertility
Basking Ridge, New Jersey
This study aims to assess the effect of age of the male partner and the reproductive ability of sperm prepared via sperm selection devices (Zymot) compared to routine embryologist selected sperm after density gradient centrifugation (DGC) preparation for intracytoplasmic sperm injection (ICSI) in patients undergoing in vitro fertilization treatment (IVF) of their infertility.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 41
Sex:Female
Key Eligibility Criteria
Disqualifiers:Azoospermia, Oligozoospermia, Donor Sperm, Others
100 Participants Needed
GnRH Agonist for Infertility
Hasbrouck Heights, New Jersey
During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 40
Sex:Female
Key Eligibility Criteria
Disqualifiers:Day 3 Transfers
350 Participants Needed
Influenza Vaccine for Infertility
New York, New York
This trial is testing if a flu shot can help women undergoing IVF get pregnant. The study focuses on women who have had trouble with miscarriages or embryo implantation. Researchers think the flu shot might make the immune system more supportive of pregnancy.
Trial Details
Trial Status:Enrolling By Invitation
Age:21 - 38
Sex:Female
Key Eligibility Criteria
Disqualifiers:Not Listed
238 Participants Needed
AI Analysis of 3D Ultrasound for IVF Outcomes
New York, New York
The use of machine learning techniques using an artificial intelligence tool is proposed to analyze clinical data to predict best possible IVF/ART outcomes. This tool has been utilized to accurately predict embryo quality here at Cornell. Utilizing this tool to assess objective clinical findings and predict outcomes of assisted reproductive techniques is sought, with the ultimate goal of an automated tool to reduce implicit physician bias. Within this goal, using this tool to objectively and accurately assess baseline ovarian reserve at the start of an ART cycle is proposed, using 3D sonography to image the ovary and artificial intelligence tool to objectively identify baseline antral follicle counts.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
4000 Participants Needed
Gamete Treatment for Infertility
New York, New York
In this proposed research study, the investigators plan to assess the efficacy of gametes' (egg and sperm) treatment on fertilization as well as pre- and post-implantation embryo development.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 89
Key Eligibility Criteria
Disqualifiers:Ivf Without Icsi, Others
1200 Participants Needed
Sperm Sorting for Gender Selection in Infertility Treatment
New York, New York
This trial is testing a method to choose sperm that will result in either a boy or a girl before fertilization. It targets couples undergoing infertility treatment. The process involves sorting sperm by density to identify male or female sperm, then using them for fertilization procedures like IVF or intrauterine insemination.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Severe Male Factor
2000 Participants Needed
Escitalopram for Sperm DNA Fragmentation
New York, New York
This trial is testing the effects of escitalopram, a common antidepressant, on healthy men with normal fertility and no history of mental health issues. Researchers want to see if this medication affects sperm quality and overall fertility. The results will help doctors advise men who are concerned about fertility and are taking or considering taking escitalopram.
Trial Details
Trial Status:Recruiting
Age:18 - 65
Sex:Male
Key Eligibility Criteria
Disqualifiers:Azoospermia, Psychiatric Disorders, Alcohol, Others
Must Not Be Taking:Psychotropics, Anticonvulsants, MAOIs, TCAs
70 Participants Needed
Abstinence Period for Male Infertility
New York, New York
The goal of this study is to learn about the impact of abstinence periods on sperm quality in healthy males 20-45 years of age with no significant comorbidities who are able to produce a semen sample via masturbation. The main question it aims to answer is:
• Do shorter abstinence periods result in improved semen quality?
Participants will provide semen samples for analysis following abstinence periods of 7 days, 5 days, 2 days, 1 day, and 3 hours.
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:20 - 45
Sex:Male
Key Eligibility Criteria
Disqualifiers:Not Listed
100 Participants Needed
PRP for Diminished Ovarian Reserve
New York, New York
Consenting women with evidence of poor ovarian reserve will be randomly assigned to treatment with either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP).
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 44
Sex:Female
Key Eligibility Criteria
Disqualifiers:Thrombocytopenia, Blood Diseases, Autoimmune, Others
Must Not Be Taking:Anticoagulants, Antiaggregants
90 Participants Needed
Luteal Stimulation vs. Estrogen Priming for Diminished Ovarian Reserve
Manhasset, New York
Ovarian reserve defines the quantity and quality of the ovarian primordial follicular pool. Diminished ovarian reserve (DOR) indicates a reduction in the quantity of ovarian follicular pool to less than expected for age. It is an important cause of infertility in many couples.
To date, there is no clear consensus in the literature on the definition of diminished ovarian reserve, and it is unclear whether low oocyte yield results from an abnormal atresia rate of the follicle pool, or from a lower follicle pool at birth or whether it can just occur as a normal variation in the population.
The ovarian response to controlled ovarian stimulation with gonadotropins (for example, for in vitro fertilization) is largely determined by the ovarian reserve, and there are numerous different ovarian stimulation protocols that are employed to try and increase the oocyte yield of a particular cycle. There is no consensus on which, if any, of these protocols are superior and preferred for patient with DOR.
Luteal gonadotropin stimulation is a protocol of controlled ovarian stimulation (COS) for use in assisted reproductive technologies (ART) that has emerged over the past decade as an acceptable alternative to the classic follicular gonadotropin stimulation.
The luteal estradiol patch protocol was introduced in 2005 in patients with poor response to controlled ovarian stimulation (COS) and to address the phenomenon of early follicle recruitment in patients with diminished ovarian reserve (DOR). Luteal gonadotropin stimulation can potentially achieve the same effect by initiating follicular recruitment for IVF prior to the body's own premature recruitment.
Our hypothesis is that the luteal stimulation protocol and estradiol priming protocol are equivalent with regard to the outcome of number of mature oocytes retrieved. Patients who will be undergoing controlled ovarian stimulation and who have a diagnosis of diminished ovarian reserve will be considered for this trial, and enrolled if meeting all inclusion and no exclusion criteria.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:20 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Ovarian Cyst, Anovulation, Breast Cancer, Others
Must Be Taking:Gonadotropins
142 Participants Needed
BAIBYS Sperm Selection for Male Infertility
Stamford, Connecticut
This study looks at an investigational automated, artificial intelligence (AI)-based sperm selection technology called the BAIBYS™ System. We want to see how it compares to current methods in terms of efficiency and effectiveness in producing high-quality Embryos, which can lead to successful pregnancies and healthy babies.
Infertility impacts about 15% of couples globally, with male issues contributing to around 50% of these cases. You will be undergoing a treatment called Intra-Cytoplasmic Sperm Injection (ICSI) as part of your planned treatment program. In this procedure, embryologists inject selected sperm into an egg, based on its movement, observed under a low-magnification microscope. However, this method does not fully detect defects in sperm shape that may indicate sperm quality. Recent studies show that using high magnification for sperm selection is important for successful fertilization, higher embryo quality, lower birth defect rates, and higher birth rates of healthy babies.
Selecting sperm manually under a microscope at high magnification takes a lot of time and depends on the skill of embryologists, which can lead to differences in judgment. Because of this, there is an interest in using AI to make sperm selection more accurate, consistent, and faster.
The BAIBYS™ System uses advanced AI technology to automatically choose sperm based on their movement, size, and shape. These features help to determine the sperm's potential to be normal and produce a good embryo. The system also organizes the selected sperm into separate areas from which the embryologist will pick the sperm for injection into the egg. This investigational device could become a valuable tool in reproductive technology. Clinical research is crucial to confirm these ideas and show their long-term effects on fertility treatments.
In this study, half of the oocytes retrieved during your IVF cycle will be injected with sperm selected from your partner's (or known donor's) semen by using the BAIBYS™ System, while the other half will be fertilized by sperm chosen according to the standard procedure at this institution. In any case, the embryologist will confirm that the sperm selected by the device are viable and acceptable. After fertilization, the best embryo, no matter which study group, will be selected for transfer to the uterus for pregnancy, and the rest of the good embryos will be frozen based on the institution's best standard clinical guidelines.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:21 - 42
Key Eligibility Criteria
Disqualifiers:Severe Endometriosis, Adenomyosis, Oncology Treatment, Others
150 Participants Needed
Follitropin Delta + HP-hMG for In Vitro Fertilization
Ottawa, Ontario
The goal of this clinical trial is to evaluate the safety and effectiveness of a personalized ovarian stimulation regimen in women aged 18 to 40 undergoing in vitro fertilization (IVF). The main question it aims to answer is:
- Does personalizing the starting doses of follitropin delta (REKOVELLE) and HP-hMG (MENOPUR) based on both age and body lead to similar results as anti-Müllerian hormone (AMH) and weight based dosing ?
Researchers will compare the new dosing regimen to the MARCS study results to see if this new approach leads to similar outcomes
Participants will:
* Receive ovarian stimulation using a personalized dose of REKOVELLE aND MENOPUR based on age and weight
* Be monitored through ultrasound imaging and blood tests to measure estradiol (E2) levels
* Undergo standard IVF procedures including egg retrieval and embryo assessment
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 40
Sex:Female
Key Eligibility Criteria
Disqualifiers:Endometriosis III/IV, OHSS Risk, Others
Must Not Be Taking:Hormonal Preparations
200 Participants Needed
Testicular Tissue Freezing for Children with Cancer
Rochester, Minnesota
This protocol is being designed to offer testicular tissue cryopreservation to male pediatric patients (0-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:0 - 17
Sex:Male
Key Eligibility Criteria
Disqualifiers:Psychiatric Conditions, Anesthesia Risk, Gonadotoxic Therapy, Others
200 Participants Needed
Progesterone Supplementation for Frozen Embryo Transfer
Montreal, Quebec
Endometrin is a progesterone supplement prescribed during in vitro fertilization (IVF) for preparation for embryo transfer. The usual dose of Endometrin is 100 mg two to three times per day in the form of an effervescent tablet to be inserted vaginally.
The purpose of this research project is to evaluate the dose response of the Endometrin when determined based on the blood level of progesterone on the day of the FET. According to the literature, a predefined level of progesterone in the blood should be reached in order to have favorable conditions for pregnancy. The hypothesis being that a woman with low progesterone levels would benefit from a dose of Endometrin of 600 mg (200 mg 3x/day) to decrease the risk of miscarriage and improve the chances of pregnancy. Women with adequate progesterone levels according to the literature, would continue with the standard dose of progesterone prescribed at clinique ovo which is 300 mg (100 mg 3x/day).
PIBF (Progesterone Induced Blocking Factor) levels, a protein found in the blood that could also predict pregnancy outcomes in women using IVF will also be looked at.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 42
Sex:Female
Key Eligibility Criteria
Disqualifiers:Cancer, Thromboembolism, Renal Disease, Others
Must Be Taking:Progesterone
150 Participants Needed
Topical Infliximab for Corneal Melt
Montreal, Quebec
This trial tests infliximab eye drops on patients with severe eye thinning due to autoimmune diseases. The drops aim to reduce inflammation by blocking a harmful protein. The study will check if these drops are safe and effective. Infliximab has been used effectively in various forms of eye inflammation, including uveitis and scleritis, often when other treatments have failed.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Infections, Neoplasia, Diabetes, Heart Failure, Others
Must Not Be Taking:Anti-TNF, Anakinra
12 Participants Needed
Genetic Counseling for Inherited Disorders
Minneapolis, Minnesota
The goal of the GC-PRO study is to try to make genetic counseling better for people of all backgrounds. We are asking participants to complete two surveys and to allow audio recording of their genetic counseling visit. The purpose of the study is to understand whether trying different ways of doing genetic counseling will lead to better experiences for patients. The research team is also working with partners from the Somali, Latino/Hispanic, Black/African American, and Hmong communities to make sure the research is being done in a way that will benefit underserved communities.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Unable To Provide Consent, Others
994 Participants Needed
Why Other Patients Applied
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
Genetic Testing for Infertility
Waltham, Massachusetts
The GETSET trial is a prospective randomized trial designed to evaluate the clinical outcomes of incorporating preimplantation genetic testing for aneuploidies (PGT-A) in elective single embryo transfer in women between 35 and 40 years of age.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:35 - 40
Sex:Female
Key Eligibility Criteria
Disqualifiers:Donor Oocytes, Gestational Carrier, RPL, Others
240 Participants Needed
Patient Navigator Program for Infertility
Boston, Massachusetts
This investigators will conduct a pilot study investigating the implementation of an infertility Patient Navigator (PN) program to mitigate challenges for underserved individuals at Boston Medical Center (BMC) seeking infertility care. The primary objective is to assess whether the PN program can significantly reduce time to completion of infertility evaluation and to initiation of fertility treatment (if recommended) for infertile patients from an underserved patient population.
The study aims are to:
1. evaluate the impact of the PN program on timelines including obtaining commercial insurance coverage for infertility, expediting labwork/imaging, weight management, and partner urology appointments, and initiating fertility treatment; and
2. ascertain the medical literacy of participants with a validated tool to assess the impact of low medical literacy on PN facilitation.
Participants will be contacted by the PN and provided with a survey instrument that will test their medical literacy. Then the PN will assist with scheduling cycle-based testing including labwork and uterine cavity evaluation, the partner's urology appointment, the patient's appointments such weight management/nutrition referral, mammograms (if indicated by age), and insurance counseling if the participant's current insurance does not cover infertility diagnostic testing and treatment. These tasks are part of pursuing fertility care at BMC.
Duration of evaluation and time to treatment in age-matched control patients from the year prior that did not have PN services will be utilized as a comparison group.
Regression analyses will be conducted to explore the association between utilization of a PN and pregnancy rates, considering potential confounding factors.
Establishment of the pilot program will enable the investigators to apply for a larger institutional patient care grant going forward. Strategies developed through this research can may enhance fertility care access for underserved communities across various healthcare settings. By tailoring interventions to populations not usually able to access specialized healthcare services, this study pioneers a paradigm shift towards inclusivity and equity in reproductive medicine.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 43
Sex:Female
Key Eligibility Criteria
Disqualifiers:Non-English Speaking, Others
40 Participants Needed
Hysterectomy and Weight Loss Surgery for Endometrial Cancer
Boston, Massachusetts
To assess the feasibility of an expedited referral process for the obese endometrial cancer or EIN patient from her gynecologic oncologist to the Brigham Center for Metabolic and Bariatric Surgery (CMBS) in order to undergo concurrent weight loss surgery and hysterectomy within 8 weeks of first appointment with a gynecologic oncologist (or 12 weeks for EIN patients).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Smoking, Substance Abuse, Others
30 Participants Needed
Catheter Caps for Dialysis
Jacksonville, Florida
The purpose of this research is to evaluate patient comfort and ease of an investigational device called Catheter Caps Case (C3) attached to the hemodialysis catheter over a 15-minute period. You have been asked to take part in this research because you have been identified as a dialysis patient with a hemodialysis catheter.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Delayed Graft Function, Acute Kidney Injury, Others
10 Participants Needed
The objectives of this study is to evaluate the PK and the dose-proportionality of FSH and HCG following a single dose of Gonadotropins-IBSA, administered subcutaneously.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Hepatitis, HIV, Pregnancy, Drug Abuse, Others
Must Be Taking:Oral Contraceptives
28 Participants Needed
Pharmacokinetics of FSH and hCG after multiple subcutaneous injection of Gonadotropins-IBSA.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Drug Abuse, Alcohol Abuse, Others
Must Be Taking:Oral Contraceptives
28 Participants Needed
This trial is testing if washing the uterus with saltwater before ovulation can help women aged 18-37 who have unexplained infertility. The treatment might work by clearing out debris or changing inflammation in the uterus to make it easier to get pregnant.
Trial Details
Trial Status:Active Not Recruiting
Age:18 - 37
Sex:Female
Key Eligibility Criteria
Disqualifiers:Not Listed
192 Participants Needed
Hera System for Infertility
Winter Park, Florida
This trial aims to see if using the Hera System can improve pregnancy rates in patients undergoing fertility treatments. The system helps embryologists choose the best embryos by providing extra information, potentially increasing the chances of pregnancy.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:21 - 43
Sex:Female
Key Eligibility Criteria
Disqualifiers:Not Listed
440 Participants Needed
Myo-Inositol + Letrozole for PCOS Infertility
Oklahoma City, Oklahoma
This will be a prospective, double-blind randomized clinical trial of letrozole and placebo versus letrozole and inositols for up to 5 treatment cycles of ovulation induction or until pregnancy is achieved. All participants and members of the research team will be blinded to the treatment arms. Placebo and inositol supplement will be packaged to appear the same, tested, and packaged by a commercial supply company. The inositols will be a 40:1 blend of myo-inositol and D-chiro inositol.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 36
Key Eligibility Criteria
Disqualifiers:Diabetes, Thyroid Dysfunction, Others
Must Not Be Taking:Myo-inositol, Metformin
168 Participants Needed
Uterine Transplant for Infertility
Dallas, Texas
This study aims to investigate the treatment of absolute uterine infertility (AUI) due to congenital or surgical absence of a uterus or presence of a nonfunctioning uterus. The investigators will follow a model based on a Swedish study to enroll 20 women with functioning ovaries and successfully transplant the uterus from either a living or cadaveric donor, with the goal of live birth after transplantation.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:20 - 35
Sex:Female
Key Eligibility Criteria
Disqualifiers:Diabetes, Hypertension, Cancer, Obesity, Others
Must Not Be Taking:Tacrolimus, Thymoglobulin, CellCept
20 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do Infertility clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Infertility clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Infertility trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Infertility is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Infertility medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Infertility clinical trials?
Most recently, we added Ovarian Tissue Transplantation for Premature Ovarian Failure, BAIBYS Sperm Selection for Male Infertility and Follitropin Delta + HP-hMG for In Vitro Fertilization to the Power online platform.
Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.